Evidence map›Paper›PMID 25389114›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2015

Validation of a coding algorithm to identify bladder cancer and distinguish stage in an electronic medical records database.

Ronac Mamtani, Kevin Haynes, Ben Boursi, Frank I Scott, David S Goldberg, Stephen M Keefe, David J Vaughn, S Bruce Malkowicz, James D Lewis

Abstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Serum glucose and hemoglobin A1C levels at cancer diagnosis and disease outcome.European journal of cancer (Oxford, England : 1990) · 2016
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ronac MamtaniAbramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania. Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania. ronac.mamtani@uphs.upenn.edu.
Kevin HaynesCenter for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania.
Ben BoursiCenter for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania. Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Frank I ScottCenter for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania.
David S GoldbergCenter for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania.
Stephen M KeefeAbramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.
David J VaughnAbramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.
S Bruce MalkowiczAbramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.
James D LewisCenter for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania.

Funding

INSTITUTIONAL CLINICAL AND TRANSLATIONAL SCIENCE AWARDUL1RR024134 · NCRR · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2006 to 2011
$70.4M
Physician Scientist Training in Clinical OncologyK12CA076931 · NCI · UNIVERSITY OF PENNSYLVANIA · PI STEPHEN Patrick HUNGER, LYNN M. SCHUCHTER · 1997 to 2026
$16.5M
Test-Treat strategy to prevent ulcerative colitis relapseK24DK078228 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI LEWIS, JAMES D · 2007 to 2016
$1.9M
A population-based cohort to study outcomes in end-stage liver disease patientsK08DK098272 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI GOLDBERG, DAVID SETH · 2013 to 2017
$786k
Microvascular disease, statins, ACE-inhibitors and post-operative SBOK08DK095951 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI SCOTT, FRANK IRVING · 2012 to 2016
$771k
NCI NIH HHS K12 CA 076931NCI NIH HHS K12 CA076931NCRR NIH HHS UL1 RR024134NCRR NIH HHS UL1-RR024134NIDDK NIH HHS K08 DK095951NIDDK NIH HHS K08-DK095951-02NIDDK NIH HHS K08 DK098272NIDDK NIH HHS K08-DK098272-01NIDDK NIH HHS K24 DK078228NIDDK NIH HHS K24-DK078228
6 · The paper itself

Abstract

Studies on outcomes in bladder cancer rely on accurate methods to identify patients with bladder cancer and differentiate bladder cancer stage. Medical record and administrative databases are increasingly used to study cancer incidence, but few have distinguished cancer stage, and none have focused on bladder cancer. In this study, we used data from The UK Health Improvement Network (THIN) to identify patients with bladder cancer using at least one diagnostic code for bladder cancer, and distinguish muscle-invasive from non-invasive disease using a subsequent code for cystectomy. Algorithms were validated against a gold standard of physician-completed questionnaires, pathology reports, and consultant letters. Algorithm performance was evaluated by measuring positive predictive value (PPV) and corresponding 95% confidence interval (CI). Among all patients coded with bladder cancer (n = 194), PPV for any bladder cancer was 99.5% (95% CI, 97.2-99.9). PPV for incident bladder cancer was 93.8% (95% CI, 89.4-96.7). PPV for muscle-invasive bladder cancer was 70.1% (95% CI, 59.4-79.5) in patients with cystectomy (n = 95) and 83.9% (95% CI, 66.3-94.5) in those with cystectomy plus additional codes for metastases and death (n = 31). Using our codes for bladder cancer, the age- and sex-standardized incidence rate (SIR) of bladder cancer in THIN approximated that measured by cancer registries (SIR within 20%), suggesting that sensitivity was high as well. THIN is a valid and novel database for the study of bladder cancer. Our algorithm can be used to examine the epidemiology of muscle-invasive bladder cancer or outcomes following cystectomy for patients with muscle invasion.

Indexed as

AgedAlgorithmsCross-Sectional StudiesElectronic Health RecordsFemaleHumansMaleSurveys and QuestionnairesUrinary Bladder Neoplasms

Identifiers

PMID25389114
PMCPMC4294969

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.